MC10 Appoints Board Member
This article was originally published in Scrip
Executive Summary
MC10, a private company focused on improving human health through digital healthcare solutions, has appointed Eric K. Brandt to its board of directors. Brandt previously served as executive vice president and chief financial officer (CFO) of Broadcom Corp., from March 2007 to January 2016, but before this he was president and CEO of Avanir Pharmaceuticals. Prior to Avanir, he was executive vice president of finance and technical operations and CFO of Allergan Inc.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.